Suppr超能文献

依诺沙星对环丙沙星、氟罗沙星、洛美沙星、氧氟沙星、培氟沙星和芦氟沙星的体外抗尿路病原体活性。

In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.

作者信息

Naber K G, Well M, Hollauer K, Kirchbauer D, Witte W

机构信息

Urologic Clinic, St. Elisabeth Hospital, Straubing, Germany.

出版信息

Chemotherapy. 1998 Mar-Apr;44(2):77-84. doi: 10.1159/000007096.

Abstract

Minimum inhibitory concentrations (MIC) of enoxacin, ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin and rufloxacin were determined against 400 uropathogens cultured from the urine of patients with complicated and/or hospital-acquired urinary tract infections (UTI) using an agar dilution method. The bacterial spectrum consisted of Entero-bacteriaceae (34.5%), enterococci (31.5%), staphylococci (21.2%) and non-fermenting bacteria (12.8%). Enoxacin inhibited all but one strain (Enterobacter cloacae) of Enterobacteriaceae up to an MIC of 1 mg/l (MIC90 0.25 mg/l). Regarding the total bacterial spectrum, enoxacin inhibited 54.5, 59.5, 76.0 and 83.8% up to an MIC of 1, 2, 4 and 8 mg/l, respectively. If the same breakpoint of resistance for ofloxacin according to DIN 58,940 (NCCLS), i.e. MIC > or = 4 mg/l (> or = 8 mg/l), is also taken for the other fluoroquinolones, and the 126 strains of enterococci are excluded, for which alternative agents, e.g. aminopenicillins, should be considered instead, the following resistance rates were found: ciprofloxacin and enoxacin 15.3% (15.0%), ofloxacin 17.2% (15.3%), pefloxacin 18.2% (15.3%), fleroxacin 19.3% (15.3%), lomefloxacin 19.7% (17.9%) and rufloxacin 31.8% (27.4%). According to their in vitro activity, all fluoroquinolones tested besides rufloxacin show similar rates of resistance against uropathogens and can therefore be considered good alternative agents for the treatment of complicated UTI.

摘要

采用琼脂稀释法,对从患有复杂性和/或医院获得性尿路感染(UTI)患者尿液中培养出的400株尿路病原体测定了依诺沙星、环丙沙星、氟罗沙星、洛美沙星、氧氟沙星、培氟沙星和芦氟沙星的最低抑菌浓度(MIC)。细菌谱包括肠杆菌科(34.5%)、肠球菌(31.5%)、葡萄球菌(21.2%)和非发酵菌(12.8%)。依诺沙星对除一株阴沟肠杆菌外的所有肠杆菌科菌株的MIC均高达1mg/l(MIC90为0.25mg/l)。就整个细菌谱而言,依诺沙星在MIC为1、2、4和8mg/l时分别抑制54.5%、59.5%、76.0%和83.8%的菌株。如果根据DIN 58940(NCCLS)对氧氟沙星的相同耐药断点,即MIC≥4mg/l(≥8mg/l),也用于其他氟喹诺酮类药物,并且排除126株肠球菌(对于这些菌株应考虑使用替代药物,如氨基青霉素),则发现以下耐药率:环丙沙星和依诺沙星为15.3%(15.0%),氧氟沙星为17.2%(15.3%),培氟沙星为18.2%(15.3%),氟罗沙星为19.3%(15.3%),洛美沙星为19.7%(17.9%),芦氟沙星为31.8%(27.4%)。根据它们的体外活性,除芦氟沙星外,所有测试的氟喹诺酮类药物对尿路病原体的耐药率相似,因此可被视为治疗复杂性UTI的良好替代药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验